Related Experiment Video
Updated: Aug 26, 2025
Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma
Irina Korovina1,2, Anne Vehlow1,3, Achim Temme4,3,5
1OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Background:
Glioblastoma (GBM) is a fast-growing primary brain tumor characterized by high invasiveness and resistance. This results in poor patient survival. Resistance is caused by many factors, including cell-extracellular matrix (ECM) interactions. Here, we addressed the role of adhesion protein integrin α2, which we identified in a high-throughput screen for novel potential targets in GBM cells treated with standard therapy consisting of temozolomide (TMZ) and radiation.
Methods:
In our study, we used a range of primary/stem-like and established GBM cell models in vitro and in vivo. To identify regulatory mechanisms, we employed high-throughput kinome profiling, Western blotting, immunofluorescence staining, reporter, and activity assays.
Results:
Our data showed that integrin α2 is overexpressed in GBM compared to normal brain and, that its deletion causes radiochemosensitization. Similarly, invasion and adhesion were significantly reduced in TMZ-irradiated GBM cell models. Furthermore, we found that integrin α2-knockdown impairs the proliferation of GBM cells without affecting DNA damage repair. At the mechanistic level, we found that integrin α2 affects the activity of activating transcription factor 1 (ATF1) and modulates the expression of extracellular signal-regulated kinase 1 (ERK1) regulated by extracellular signals. Finally, we demonstrated that integrin α2-deficiency inhibits tumor growth and thereby prolongs the survival of mice with orthotopically growing GBM xenografts.
Conclusions:
Taken together our data suggest that integrin α2 may be a promising target to overcome GBM resistance to radio- and chemotherapy. Thus, it would be worth evaluating how efficient and safe the adjuvant use of integrin α2 inhibitors is to standard radio(chemo)therapy in GBM.
Insights
Targeting integrin α2 shows promise in overcoming glioblastoma (GBM) resistance to standard therapy. Inhibiting this adhesion protein sensitizes GBM cells to radiation and chemotherapy, improving survival in preclinical models.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis due to invasiveness and treatment resistance.
- Cell-extracellular matrix (ECM) interactions contribute to GBM resistance.
- Integrin α2 was identified as a potential therapeutic target in GBM cells treated with temozolomide (TMZ) and radiation.
Purpose of the Study:
- To investigate the role of integrin α2 in GBM resistance to standard therapy.
- To elucidate the mechanisms by which integrin α2 influences GBM cell behavior and treatment response.
Main Methods:
- Utilized various GBM cell models (in vitro and in vivo).
- Employed high-throughput kinome profiling, Western blotting, immunofluorescence, and reporter assays.
- Assessed effects of integrin α2 knockdown on GBM cell proliferation, invasion, adhesion, and DNA repair.
Main Results:
- Integrin α2 is overexpressed in GBM and its deletion enhances sensitivity to radiochemotherapy.
- Integrin α2 knockdown significantly reduced GBM cell invasion and adhesion.
- Integrin α2 deficiency impaired GBM cell proliferation without affecting DNA repair, and prolonged survival in mouse models.
Conclusions:
- Integrin α2 is a potential therapeutic target for overcoming GBM resistance to radio- and chemotherapy.
- Further evaluation of integrin α2 inhibitors as adjuvant therapy for GBM is warranted.
